Drug Trial Radar · NCT02573025
A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration
Last checked: Nov 19, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Actual
Start
Sep 17, 2015
Primary completion
Apr 11, 2016
Study completion Apr 11, 2016
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, multi-center, single dose, two-period, two-sequence crossover study to investigate the bioequivalence of PEG-IFN alfa-2a BA-free formulation versus the reference market formulation (PEG-IFN alfa-2a \[Pegasys®\]) following subcutaneous administration via prefilled syringe in healthy Chinese participants.
Conditions
- Healthy Volunteers
Interventions
PEG-IFN alfa-2a BA-free formulation (Test)Drug
Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
PEG-IFN alfa-2a market formulation (Reference)Drug
Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax) for PEG-IFN alfa-2aTime frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
- Area Under the Concentration-Time Curve (AUC) for PEG-IFN alfa-2a From Time Zero to 816 hours (AUC0-816h)Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
CMAX A division of IDT Australia Limited
Adelaide, South Australia, Australia
The University of Hong Kong; Pharmacy Clinical Trials
Hong Kong, Hong Kong
The Chinese University of Hong Kong; Emergency Medicine
Shatin, Hong Kong
Christchurch Clinical Studies Trust
Christchurch, New Zealand
Auckland Clinical Studies Limited
Grafton, New Zealand
SingHealth Investigational Medicine Unit; Haematology
Singapore, Singapore
Changi General Hospital- Parent; Department of Rheumatology
Singapore, Singapore
China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H
Taichung, Taiwan
Taipei Medical University Hospital; Clinical Research Center
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.